Feed QGEN
QG

Qiagen

QGEN · NYSE

$43.69 -2.43% (-$1.09)
1M +7.18%
Market Cap $9.23B
P/E Ratio 22.55x
Div. Yield 0.78%
ROE 11.60%

Bulios Fair Price

$32.63

25.3% downside

Trenutna cena

$43.69

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica QGEN trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
7/9
Valuation
61 /100
Fair
P/E 22.55x
EV/EBITDA 13.73x
P/S 4.40x
Growth
17 /100
Declining
EPS growth 0.16%
Rev. growth 0.81%
FCF growth 7.13%
Profitability
100 /100
Strong
Gross margin 61.82%
Net margin 19.49%
Op. margin 25.33%
Quality
50 /100
Average
ROIC 8.86%
ROE 11.60%
ROA 6.95%
Debt
89 /100
Low
Debt/Equity 0.49x
Current ratio 2.85x
Int. coverage 12.71x
Stability
70 /100
Stable
Beta 0.63x
Rev. volatility 7.03%
EPS volatility 281.53%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o QGEN
Online

O podjetju

Qiagen N.V. (QGEN) is a Dutch company specializing in providing innovative diagnostic tests and technologies in the field of molecular biology. With a broad portfolio of products and services including tests for genetic mutations, infectious disease diagnostics, and analytical tools for genetic material research, Qiagen is one of the leading providers of diagnostic solutions in the market. The company focuses on providing accurate, reliable, and fast diagnostic tests that assist physicians and researchers in identifying and treating diseases. Qiagen also invests in innovation and the development of new diagnostic technologies to continuously improve patient diagnosis and treatment. Qiagen N.V. (QGEN) shares could be suitable for investors looking to invest in biotechnology companies with a focus on molecular diagnostics and innovative research and development in the healthcare sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Jon Pratt

Employees

5,500

Headquarters

Venlo

Prihajajoči dogodki

03 NOV.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.